32 Biosciences
32 Biosciences
32 Biosciences is a biotechnology company focused on preventing and treating gastrointestinal (GI) diseases by restoring and protecting the gut mucosal-immune system. The company combines a first-in-class therapeutic program with a proprietary GI discovery platform to measure metabolomic signatures of the gut mucosal-immune system and enable therapeutic discovery, development, and clinical decision support.
Our Mission
Our mission is to restore gut mucosal-immune health and deliver metabolomic and data-driven insights that accelerate therapeutic discovery, improve patient outcomes, and transform standards of care across high-burden GI diseases. We prioritize prevention and restoration of the mucosal-immune barrier to reduce infection risk, chronic inflammation, and disease recurrence.
Platforms & Pipeline
- CS Therapeutic Pipeline — Mucosal Immune Modulator (MIM) therapeutics that restore and protect the GI mucosal-immune barrier. Lead asset: CS-0003.
- GB: GI Discovery Platform — Quantifies metabolomic signatures of the gut mucosal-immune system to support discovery, development, and clinical decision support.